Researchers at GlaxoSmithKline have been awarded grants to develop new treatments for HIV/AIDS. Dr. Yaoxing Huang's work focuses on designing a protein that can block all three steps of the viral entry process, while Olaf Kutsch aims to identify potential inhibitors of HIV transcription using a novel screening system.
The GlaxoSmithKline Drug Discovery and Development Research Grant Program provides funding for HIV/AIDS research, focusing on novel therapies, vaccines, and microbicides. Researchers can apply for grants ranging from $25,000 to $150,000 to develop innovative treatments and submit proposals for publication.
The GSK Drug Discovery and Development Research Grant Program awarded $125,000 grants to Paul Bieniasz for genetic screening of cyclic peptides and Michael Farzan for tyrosine-sulfated peptides. Additionally, Michael H. Malim received a grant for his research on the Vif gene, which plays a critical role in HIV infection.
Lexiva demonstrated durable anti-viral response through 48 weeks, significantly less grade 2-4 drug-related diarrhea than nelfinavir. In PI-experienced patients, Lexiva/r showed fewer nucleoside reverse transcriptase inhibitor (NRTI) mutations after virologic failure compared to lopinavir/ritonavir.
Pharmacokinetic data suggest that 908 can be co-administered with Maalox TC or Zantac without dose adjustments. Co-administration with Lipitor increased ATO exposure but did not affect 908 PK.
A multicenter study of 770 individuals found that a once-daily Abacavir regimen achieved similar virologic responses as the traditional twice-daily dosing regimen, with 66% achieving undetectable HIV-1 RNA levels. The regimen was also found to have a similar safety profile, with minimal hypersensitivity reactions reported.
An interim analysis of a study comparing TDF to EFV in combination with 3TC + ABC found that the TDF arm had a higher rate of virologic non-response. The study included 194 patients and showed that VL <400 copies/mL was achieved in 49% of TDF subjects, compared to 90% of EFV subjects.
The study found that the three-drug combination of abacavir, lamivudine, and efavirenz provided a potent antiretroviral response over 48 weeks. Subjects in the ABC/3TC/EFV group had a significantly better immunologic response compared to those in the ZDV/3TC/EFV group.
Studies link early life risk factors to dementia onset and suicidal tendencies in older adults. Drivers Rehabilitation Programs may improve elderly driver safety. Most doctors fail to recognize early signs of Alzheimer's and cognitive impairment in their patients.
The GSK Drug Discovery and Development Research Grant Program provides funding for innovative research into HIV/AIDS treatments. Researchers will be selected based on the potential importance of their project, originality, and ability to conduct the proposed research.
Similar efficacy responses were seen in both the 908/r regimens and the LPV/r regimen, meeting the primary endpoint of non-inferiority at 24 weeks. Patients achieved positive antiviral responses with both 908/r and LPV/r regimens.
The Phase III, 48-week NEAT study found that 66% of patients taking 908 achieved undetectable viral load compared to 51% on nelfinavir. The study also showed improved safety and efficacy profiles for 908, with lower rates of adverse events and virologic failures.
A recent study found a decrease in thymidine analog mutations and an increase in K65R and Y115F mutations associated with HIV treatment failure. The study analyzed data from 1999-2002 and identified trends in antiretroviral therapy usage and mutation incidence.
The study found that boosting GW433908 with ritonavir reduced the incidence of PI-resistance selected by either the study PI or NRTIs ABC and 3TC. In contrast, unboosted 908 had a higher rate of resistance to 3TC and some patients developed mutations associated with APV resistance.
In the 48-week SOLO trial, patients taking GW433908/r QD achieved undetectable viral load in 68%, compared to 65% of those taking nelfinavir BID. The study also showed improved efficacy in patients with high or low CD4 counts at baseline.
A survey of 299 HIV+ patients found that total pills per day had the greatest impact on adherence, followed by dosing frequency. Patients preferred low-pill-count regimens and those requiring less frequent dosing.
Researchers Irwin Chaiken, Nouri Neamati, Alan C. Sartorelli, Nan-Sook Lee, Elias Lolis, and Min Lu received awards for their work on preventing HIV from infecting host cells, developing integrase inhibitors, and making current drugs more effective. The $500,000 award aims to encourage new approaches in HIV/AIDS therapy research.
The GlaxoSmithKline Drug Discovery and Development Award provides funding for innovative HIV/AIDS research, including therapies aimed at treating infection and preventing transmission. The award is intended to further the development of inventive treatments for HIV/AIDS.
A study evaluated dosage adjustments of Agenerase in HIV patients taking efavirenz or nevirapine, showing that therapeutic plasma concentrations were maintained at 6 or 12 weeks. Dosage adjustments resulted in improved amprenavir levels in all cases, despite the presence of efavirenz or nevirapine.
The estimated total first year costs for diagnosing, treating, and managing FMMA range from $410 for insulin resistance to $7,368 for abnormal fat distribution, with second-year costs ranging from $115 to $3,895 depending on the symptom being treated.
A study found that 74% of patients taking Ziagen/Combivir had viral loads below 400 copies/ml at 24 weeks, compared to 57% on the PI-containing regimen. Patients on Ziagen/Combivir also reported fewer difficulties with their triple regimen. The study assessed efficacy, safety, and patient adherence in therapy-naive patients.
Two studies compare the efficacy and adherence of the triple nucleoside regimen of Ziagen/Combivir versus PI-containing regimens. Preliminary data show that patients on the Ziagen/Combivir regimen had better viral load suppression, with 68% achieving <400 copies/ml at 24 weeks, compared to 57% on the PI-containing regimen.
A preliminary study found that combining Agenerase with low-dose ritonavir increases amprenavir plasma levels, potentially improving treatment goals. The study, conducted on PI-experienced patients, showed a significant increase in amprenavir concentrations when ritonavir was added.
A new meta-analysis of 24 studies found that allergy shots can effectively treat allergic asthma in both adults and children, reducing symptoms and improving lung function. The research suggests that up to half of all adult asthmatics and an even greater proportion of children may benefit from immunotherapy.